Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Metab ; 9: 28-42, 2018 03.
Article in English | MEDLINE | ID: mdl-29428596

ABSTRACT

OBJECTIVE: The peroxisome proliferator-activated receptor-γ coactivator-1α1 (PGC-1α1) regulates genes involved in energy metabolism. Increasing adipose tissue energy expenditure through PGC-1α1 activation is potentially beneficial for systemic metabolism. Pharmacological PGC-1α1 activators could be valuable tools in the fight against obesity and metabolic disease. Finding such compounds has been challenging partly because PGC-1α1 is a transcriptional coactivator with no known ligand-binding properties. While, PGC-1α1 activation is regulated by several mechanisms, protein stabilization is a crucial limiting step due to its short half-life under unstimulated conditions. METHODS: We designed a cell-based high-throughput screening system to identify PGC-1α1 protein stabilizers. Positive hits were tested for their ability to induce endogenous PGC-1α1 protein accumulation and activate target gene expression in brown adipocytes. Select compounds were analyzed for their effects on global gene expression and cellular respiration in adipocytes. RESULTS: Among 7,040 compounds screened, we highlight four small molecules with high activity as measured by: PGC-1α1 protein accumulation, target gene expression, and uncoupled mitochondrial respiration in brown adipocytes. CONCLUSIONS: We identify compounds that induce PGC-1α1 protein accumulation and show that this increases uncoupled respiration in brown adipocytes. This screening platform establishes the foundation for a new class of therapeutics with potential use in obesity and associated disorders.


Subject(s)
Adipocytes, Brown/drug effects , Anti-Obesity Agents/pharmacology , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism , Small Molecule Libraries/pharmacology , Uncoupling Agents/pharmacology , Uncoupling Protein 1/metabolism , Adipocytes, Brown/metabolism , Animals , Anti-Obesity Agents/chemistry , Cell Respiration , HEK293 Cells , Humans , Mice , Mitochondria/drug effects , Mitochondria/metabolism , Protein Stability , Small Molecule Libraries/chemistry , Uncoupling Agents/chemistry , Uncoupling Protein 1/genetics
2.
J Biomol Screen ; 19(6): 859-69, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24632660

ABSTRACT

The CXC chemokine receptor 4 (CXCR4) is a widely expressed G protein-coupled receptor implicated in several diseases. In cancer, an increased number of surface CXCR4 receptors, in parallel with aberrant signaling, have been reported to influence several aspects of malignancy progression. CXCR4 activation by the specific ligand C-X-C motif chemokine 12 (CXCL12) induces several intracellular signaling pathways that have been selectively related to malignancy depending on the tissue or cell type. We developed a panel of CXCR4 screening assays investigating Gα(i)-mediated cyclic adenosine monophosphate modulation, ß-arrestin recruitment, and receptor internalization. All of the assays were set up in recombinant cells and were used to test four reported CXCR4 antagonists. Consequently, a set of hit compounds, deriving from a screening campaign of a 30,000-small-molecule internal library, was profiled with the different assays. We identified several compounds showing a pathway-selective activity: antagonists on a Gα(i)-dependent pathway; antagonists on both the ß-arrestin and Gα(i)-dependent pathways, some of which induce receptor internalization; and compounds with an antagonist behavior in all of the readouts. The identified biased antagonists induce different functional states on CXCR4 and preferentially affect specific downstream responses from the activated receptor, thus providing an improved therapeutic profile for correction of CXCR4 abnormal signaling.


Subject(s)
Receptors, CXCR4/antagonists & inhibitors , Animals , Arrestins/chemistry , CHO Cells , Cell Line , Cell Line, Tumor , Cell Separation , Chemokine CXCL12/chemistry , Cricetinae , Cricetulus , Cyclic AMP/chemistry , Disease Progression , Flow Cytometry , Humans , Ligands , Mass Screening , Peptides/chemistry , Phosphorylation , Recombinant Proteins/chemistry , Signal Transduction , Small Molecule Libraries/chemistry , Spectrometry, Fluorescence , beta-Arrestins/chemistry , beta-Galactosidase/chemistry
3.
Acta Biochim Pol ; 48(4): 1051-60, 2001.
Article in English | MEDLINE | ID: mdl-11995967

ABSTRACT

Monomeric (G), total (T) and filamentous (F) actin and the state of actin polymerisation (F:G) were determined and actin filaments were visualized in hepatoma Morris 5123 cells cultured in the presence of methotrexate (MTX) at various concentration. The exposure of the cells to this drug resulted in a decrease of total and polymerised actin in cytoplasm and in some changes in actin filament organization. This coincided with a decrease of the cells' ability to migrate through Matrigel coated filters and with inhibition of tumour formation after reimplantation of the methotrexate treated cells to experimental rats.


Subject(s)
Actins/metabolism , Carcinoma, Hepatocellular/drug therapy , Methotrexate/pharmacology , Animals , Antimetabolites, Antineoplastic/pharmacology , Biocompatible Materials/chemistry , Cell Movement , Collagen/pharmacology , Cytoplasm/metabolism , Cytosol/metabolism , Dose-Response Relationship, Drug , Drug Combinations , Laminin/pharmacology , Microscopy, Fluorescence , Neoplasm Invasiveness , Proteoglycans/pharmacology , Rats , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...